We are live on ! Find out more
BL

Bleichroeder LP Portfolio holdings

AUM $579M
1-Year Est. Return 94.36%
This Fund
S&P 500
This Quarter Est. Return
+5.53%
1 Year Est. Return
+94.36%
3 Year Est. Return
+196.81%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$559M
AUM Growth
-$6.54M
Cap. Flow
-$4.83M
Cap. Flow %
-0.87%
Top 10 Hldgs %
65.7%
Holding
77
New
3
Increased
6
Reduced
4
Closed
2

Top Buys

1
FGNA.U
FG New America Acquisition Corp. Units, each consisting of one share of Class A common stock and one
FGNA.U
+$5M
2
ADVM
Adverum Biotechnologies
ADVM
+$2.25M
3
TGTX icon
TG Therapeutics
TGTX
+$1.61M
4
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$1.02M
5
FATE icon
Fate Therapeutics
FATE
+$697K

Top Sells

1
ARKO icon
ARKO Corp
ARKO
+$10.3M
2
BLFS icon
BioLife Solutions
BLFS
+$3.46M
3
FLNA
Filana Therapeutics
FLNA
+$1.65M
4
DRRX
DURECT Corp
DRRX
+$501K
5
CUE icon
Cue Biopharma
CUE
+$288K

Sector Composition

1 Healthcare 22.73%
2 Industrials 17.34%
3 Energy 10.35%
4 Materials 8.21%
5 Consumer Discretionary 6.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARKO icon
76
ARKO Corp
ARKO
$893M
– –
-1,000,000
Closed -$10.3M
BLFS icon
77
BioLife Solutions
BLFS
$1.42B
– –
-211,942
Closed -$3.46M
1 2 3
4

Similar funds

BCM
Bourgeon Capital Management Darien, Connecticut $578M AUM 41.69% 1-Year Est. Return
LRIA
Leonard Rickey Investment Advisors Yakima, Washington $578M AUM 16.23% 1-Year Est. Return
WCCM
Webs Creek Capital Management Dallas, Texas $578M AUM 79.84% 1-Year Est. Return
MIOT
Massachusetts Institute of Technology Cambridge, Massachusetts $577M AUM 8.5% 1-Year Est. Return
AF
Aegis Financial Mc Lean, Virginia $580M AUM 105.74% 1-Year Est. Return
JCP
JB Capital Partners Armonk, New York $581M AUM 46.16% 1-Year Est. Return
GCM
Gibraltar Capital Management Tulsa, Oklahoma $581M AUM 18.65% 1-Year Est. Return
KNW
Kesler Norman & Wride Ogden, Utah $581M AUM 17.6% 1-Year Est. Return

Bleichroeder LP's Q3 2020 Portfolio in Review

As of Q3 2020, Bleichroeder LP held 77 positions worth $559M, down 1.2% from $565M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Bleichroeder LP's Q3 2020 filing shows 3 new, 6 increased, 4 reduced and 2 closed positions. Its largest new stake was FG New America Acquisition Corp. Units, each consisting of one share of Class A common stock and one: 500,000 shares worth $5M. The largest sale was ARKO Corp, an estimated $10.3M.

By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 26% a quarter earlier, followed by Industrials and Energy.

  • Bleichroeder LP's largest Q3 2020 buy was FG New America Acquisition Corp. Units, each consisting of one share of Class A common stock and one: 500,000 shares worth $5M.
  • Bleichroeder LP added most to Marinus Pharmaceuticals, Inc in Q3 2020, an estimated $1.02M increase.
  • Bleichroeder LP's biggest Q3 2020 reduction was Filana Therapeutics, cutting an estimated $1.65M.
  • Bleichroeder LP fully exited ARKO Corp in Q3 2020, selling an estimated $10.3M.
  • Bleichroeder LP's ten largest holdings make up 66% of its $559M portfolio in Q3 2020.
  • Bleichroeder LP opened 3 new positions and closed 2 in Q3 2020.
  • Bleichroeder LP's portfolio value fell 1.2% quarter-over-quarter to $559M.

Based on Bleichroeder LP's 13F filing for Q3 2020, filed 12 Nov 2020.